Recipharm announced the divestment of its API development and manufacturing facility in Israel to Scinai Immunotherapeutics Ltd., as part of its ongoing strategic transformation. The development, announced on February 16, 2026, reflects the company’s focus on optimizing its global manufacturing network and prioritizing core business segments.
Divestment of API Manufacturing Facility
The divested facility, located in Yavne, Israel, is a cGMP-certified site specializing in early-stage chemistry development and small-scale API manufacturing. The site has been supporting pharmaceutical and biotech companies with clinical-stage API production and process development.
By transferring ownership of this facility, Recipharm is streamlining its operations while enabling Scinai to expand its footprint in API development and manufacturing.
Strengthening Strategic Focus
The decision aligns with Recipharm’s broader strategy to focus on its core CDMO capabilities, particularly in areas such as finished dosage forms, advanced drug delivery systems, and large-scale manufacturing.
This move allows the company to allocate resources more efficiently and enhance its competitiveness in high-growth segments of the pharmaceutical manufacturing market.
Enabling Growth for Scinai
Through this acquisition, Scinai Immunotherapeutics Ltd. gains access to a fully operational API manufacturing facility with established expertise in process chemistry and early-stage production.
The integration of this facility strengthens Scinai’s ability to support drug development programs, particularly in the clinical phase, while expanding its contract development and manufacturing (CDMO) service offerings.
Expanding API Development Ecosystem
The transaction also reflects a broader industry trend toward restructuring and specialization within the pharmaceutical manufacturing value chain. Companies are increasingly focusing on specific segments while leveraging partnerships and acquisitions to maintain end-to-end capabilities.
The divestment ensures continuity of services for existing clients while enhancing operational flexibility for both organizations.
Outlook
The development announced on February 16, 2026, highlights the growing importance of strategic portfolio optimization in the API and CDMO sectors. As demand for specialized manufacturing capabilities increases, companies are expected to continue refining their operational focus through targeted acquisitions and divestments.
With this move, Recipharm is reinforcing its strategic direction, while Scinai Immunotherapeutics Ltd. strengthens its position in API development and clinical-stage manufacturing.
